Coya Therapeutics, Inc. COYA 深 滬
已收盤 05-08 16:00:00 美东时间
4.11
-0.090
-2.14%
華盛通- 最 高4.275
- 今 開4.23
- 成交量 16.57万股
- 最 低 4.06
- 昨 收 4.20
- 總市值 9640.90万
- 52周最高 7.75
- 市盈率 靜 --
- 換手率 0.71%
- 52周最低 3.7101
- 委 比 12.08%
- 總股本 2345.72万
- 歷史最高 10.6899
- 量 比 1.42
- 振 幅 5.12%
- 歷史最低 3.21
- 每 手 1
- 風險率 0.78%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Coya Therapeutics Announces Publication Demonstrating That COYA 302 Increased Three Biomarkers In ALS Patients Compared To Controls
The study evaluated serum biomarkers of lipid peroxidation, systemic inflammation, and axonal integrity in 100 randomly selected patients with ALS and included 100 healthy controls to allow for a meaningful comparison.
04-09 20:04
美股大行评级 | 瑞穗上调MongoDB至"跑赢大市"，目标价从290美元升至325美元；麦格理下调小鹏评级至"中性" 目标价从24美元降至19美元
今日重点评级关注：HC Wainwright & Co.：维持Perspective Therapeutics"买入"评级，目标价从12美元升至13美元；Litchfield Hills：维持Star Equity Holdings"买入"评级，目标价从21美元升至28美元
03-24 10:07
Coya Therapeutics Q4 EPS $(0.34) Misses $(0.28) Estimate, Sales $3.960M Beat $1.928M Estimate
Coya Therapeutics (NASDAQ:COYA) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.28) by 21.86 percent. This is a 88.89 percent decrease over losses of $(0.18) per share
03-17 05:56
Coya Therapeutics Files Prospectus To Register Resale Of 2,522,727 Common Shares Issued In Private Placement
Coya Therapeutics, Inc.2,522,727 Shares of Common StockThis prospectus relates to the resale of up to 2,522,727 shares of Coya Therapeutics, Inc. (the "Company," "we," "our," or "us") common stock, par value $0.0001 per
03-16 21:26
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers iSpecimen (NASDAQ:ISPC) shares moved upwards by 70.7% to $0.38 during ...
03-13 05:05
美股大行评级 | 潜在涨幅216.49%！杰富瑞上调BioAge Labs目标价至62美元，评级升至"买入"
今日重点评级关注：杰富瑞：上调BioAge Labs评级至"买入"，目标价从9美元升至62美元；RBC Capital：维持COMPASS Pathways Plc Sponsored ADR"跑赢大市"评级，目标价从21美元升至22美元
02-19 16:21
D. Boral Capital Maintains Buy on Coya Therapeutics, Maintains $15 Price Target
D. Boral Capital analyst Jason Kolbert maintains Coya Therapeutics (NASDAQ:COYA) with a Buy and maintains $15 price target.
02-18 20:35
美股大行评级 | 高露洁棕榄、再生元制药、伊士曼化工、威瑞森、Ameris、丘奇＆德怀特等获多家大行上调目标价
今日重点评级关注：Benchmark：维持Charter Communications"买入"评级，目标价从425美元升至455美元；BTIG：维持LifeStance Health Gr"买入"评级，目标价从10美元升至11美元
02-03 09:06
Coya Therapeutics Commences ~$11.1M Offering Of 2.522M Common Shares At $4.40/Share; Dr. Reddy's Laboratories And Greenlight Capital Are Investors In Offering
Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative
01-30 21:10
Coya Therapeutics Enters 2026 With $46.8M Cash Runway, Dr. Reddy's Partnership And Key ALS, FTD Trial Milestones Ahead
Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, releases the following letter to stockholders from Chief
01-20 21:10
